These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
319 related articles for article (PubMed ID: 17763414)
1. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Cooper MA; Willingham DL; Brown DE; French AR; Shih FF; White AJ Arthritis Rheum; 2007 Sep; 56(9):3107-11. PubMed ID: 17763414 [TBL] [Abstract][Full Text] [Related]
2. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Levine TD Arthritis Rheum; 2005 Feb; 52(2):601-7. PubMed ID: 15692974 [TBL] [Abstract][Full Text] [Related]
3. Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases. El-Hallak M; Binstadt BA; Leichtner AM; Bennett CM; Neufeld EJ; Fuhlbrigge RC; Zurakowski D; Sundel RP J Pediatr; 2007 Apr; 150(4):376-82. PubMed ID: 17382113 [TBL] [Abstract][Full Text] [Related]
4. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Chung L; Genovese MC; Fiorentino DF Arch Dermatol; 2007 Jun; 143(6):763-7. PubMed ID: 17576943 [TBL] [Abstract][Full Text] [Related]
5. Rituximab as therapy for refractory polymyositis and dermatomyositis. Noss EH; Hausner-Sypek DL; Weinblatt ME J Rheumatol; 2006 May; 33(5):1021-6. PubMed ID: 16541475 [TBL] [Abstract][Full Text] [Related]
6. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study. Dierickx D; Verhoef G; Van Hoof A; Mineur P; Roest A; Triffet A; Kentos A; Pierre P; Boulet D; Bries G; Lê PQ; Janssens A; Delannoy A J Intern Med; 2009 Nov; 266(5):484-91. PubMed ID: 19549092 [TBL] [Abstract][Full Text] [Related]
7. Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris. El Tal AK; Posner MR; Spigelman Z; Ahmed AR J Am Acad Dermatol; 2006 Sep; 55(3):449-59. PubMed ID: 16908351 [TBL] [Abstract][Full Text] [Related]
9. Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris. Faurschou A; Gniadecki R Int J Dermatol; 2008 Mar; 47(3):292-4. PubMed ID: 18289336 [TBL] [Abstract][Full Text] [Related]
10. Clinical significance of specific autoantibodies in juvenile dermatomyositis. Feldman BM; Reichlin M; Laxer RM; Targoff IN; Stein LD; Silverman ED J Rheumatol; 1996 Oct; 23(10):1794-7. PubMed ID: 8895161 [TBL] [Abstract][Full Text] [Related]
11. Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias. Rao A; Kelly M; Musselman M; Ramadas J; Wilson D; Grossman W; Shenoy S Pediatr Blood Cancer; 2008 Apr; 50(4):822-5. PubMed ID: 17570702 [TBL] [Abstract][Full Text] [Related]
12. [Refractory dermatomyositis associated with chronic organizing pneumonia treated with rituximab: report of one case]. Yáñez V J; Cisternas M M; Saldías H V; Saldías P F Rev Med Chil; 2009 Jan; 137(1):88-93. PubMed ID: 19399327 [TBL] [Abstract][Full Text] [Related]
13. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Ramanan AV; Campbell-Webster N; Ota S; Parker S; Tran D; Tyrrell PN; Cameron B; Spiegel L; Schneider R; Laxer RM; Silverman ED; Feldman BM Arthritis Rheum; 2005 Nov; 52(11):3570-8. PubMed ID: 16255046 [TBL] [Abstract][Full Text] [Related]
14. National registry of patients with juvenile idiopathic inflammatory myopathies in Hungary--clinical characteristics and disease course of 44 patients with juvenile dermatomyositis. Constantin T; Ponyi A; Orbán I; Molnár K; Dérfalvi B; Dicso F; Kálovics T; Müller J; Garami M; Sallai A; Balogh Z; Szalai Z; Fekete G; Dankó K Autoimmunity; 2006 May; 39(3):223-32. PubMed ID: 16769656 [TBL] [Abstract][Full Text] [Related]
15. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Aggarwal R; Bandos A; Reed AM; Ascherman DP; Barohn RJ; Feldman BM; Miller FW; Rider LG; Harris-Love MO; Levesque MC; ; Oddis CV Arthritis Rheumatol; 2014 Mar; 66(3):740-9. PubMed ID: 24574235 [TBL] [Abstract][Full Text] [Related]
16. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Huber AM; Lang B; LeBlanc CM; Birdi N; Bolaria RK; Malleson P; MacNeil I; Momy JA; Avery G; Feldman BM Arthritis Rheum; 2000 Mar; 43(3):541-9. PubMed ID: 10728746 [TBL] [Abstract][Full Text] [Related]
17. Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies). Niedermeier A; Eming R; Pfütze M; Neumann CR; Happel C; Reich K; Hertl M Arch Dermatol; 2007 Feb; 143(2):192-8. PubMed ID: 17309999 [TBL] [Abstract][Full Text] [Related]
18. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab). Marzano AV; Fanoni D; Venegoni L; Berti E; Caputo R Dermatology; 2007; 214(4):310-8. PubMed ID: 17460402 [TBL] [Abstract][Full Text] [Related]
19. Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features. Stringer E; Singh-Grewal D; Feldman BM Arthritis Rheum; 2008 Nov; 58(11):3585-92. PubMed ID: 18975314 [TBL] [Abstract][Full Text] [Related]
20. Predictability of the clinical course of juvenile dermatomyositis based on initial muscle biopsy: a retrospective study of 72 patients. Miles L; Bove KE; Lovell D; Wargula JC; Bukulmez H; Shao M; Salisbury S; Bean JA Arthritis Rheum; 2007 Oct; 57(7):1183-91. PubMed ID: 17907236 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]